Sanaz Memarzadeh

Dr. Sanaz Memarzadeh

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in Cancer Cell
Verified
Journal Article
Closed access
ASAlice Soragni
Alice Soragni
DJDeanna M. Janzen
Deanna M. Janzen
LJLisa M. Johnson
Lisa M. Johnson
ALAnne G. Lindgren
Anne G. Lindgren
ANAnh Thai-Quynh Nguyen
Anh Thai-Quynh Nguyen
DEDavid S. Eisenberg
David S. Eisenberg

21 August 2012 in Stem Cells
Verified
Journal Article
Open access
PDF file
DPDaniel Y. Paik
Daniel Y. Paik
DJDeanna M. Janzen
Deanna M. Janzen
ASAmanda M. Schafenacker
Amanda M. Schafenacker
VVVictor S. Velasco
Victor S. Velasco
MSMay S. Shung
May S. Shung
SMSanaz Memarzadeh
Sanaz Memarzadeh
The reproductive role of the fallopian tube is to transport the sperm and egg. The tube is positioned to act as a bridge between the ovary where the egg is released and the uterus where implantation occurs. Throughout reproductive years, the fallopian tube epithelium undergoes repetitive damage and regeneration. Although a reservoir of adult epithelial stem cells must exist to replenish damaged cells, they remain unidentified. Here, we report isolation of a subset of basally located human fallopian tube epithelia (FTE) that lack markers of ciliated (β‐tubulin; TUBB4) or secretory (PAX8) differentiated cells. These undifferentiated cells expressed cell surface antigens: epithelial cell adhesion molecule, CD44, and integrin α 6. This FTE subpopulation was fivefold enriched for cells capable of clonal growth and self‐renewal suggesting that they contain the FTE stem‐like cells (FTESCs). A twofold enrichment of the FTESC was found in the distal compared to the proximal end of the tube. The distal fimbriated end of the fallopian tube is a well‐characterized locus for initiation of serous carcinomas. An expansion of the cells expressing markers of FTESC was detected in tubal intraepithelial carcinomas and in fallopian tubes from patients with invasive serous cancer. These findings suggest that FTESC may play a role in the initiation of serous tumors. Characterization of these stem‐like cells will provide new insight into how the FTE regenerate, respond to injury, and may initiate cancer. STEM CELLS2012;30:2487–2497

1 February 2023 in Gynecologic Oncology
Verified
Journal Article
Open access
LGLucy Gilbert
Lucy Gilbert
AOAna Oaknin
Ana Oaknin
UMUrsula A. Matulonis
Ursula A. Matulonis
GMGina M. Mantia-Smaldone
Gina M. Mantia-Smaldone
PLPeter C. Lim
Peter C. Lim
DODavid M. O'MAlley
David M. O'MAlley
Evaluate the antitumor activity and safety profile of the combination of mirvetuximab soravtansine and bevacizumab in patients with platinum-resistant ovarian cancer. Patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, whose most recent platinum-free interval was ≤6 months, were administered mirvetuximab soravtansine (6 mg/kg adjusted ideal body weight) and bevacizumab (15 mg/kg), intravenously, once every 3 weeks. Eligibility included FRα expression by immunohistochemistry (IHC; ≥25% of cells with ≥2+ intensity). Prior bevacizumab and/or PARP inhibitor (PARPi) treatment were permitted. The primary endpoint was confirmed objective response rate (ORR). Secondary endpoints included duration of response (DOR), progression-free survival (PFS), and safety. Ninety-four patients received combination treatment with mirvetuximab soravtansine and bevacizumab. Median age was 62 years (range, 39-81). Fifty-two percent had ≥3 prior therapies; 59% had prior bevacizumab; and 27% had prior PARPi. ORR was 44% (95% CI 33, 54) with 5 complete responses, median DOR 9.7 months (95% CI 6.9, 14.1), and median PFS 8.2 months (95% CI 6.8, 10.0). Treatment-related adverse events were consistent with the profiles of each agent, with the most common being blurred vision (all grades 57%; grade 3, 1%), diarrhea (54%; grade 3, 1%), and nausea (51%; grade 3, 1%). The mirvetuximab soravtansine plus bevacizumab doublet is an active and well-tolerated regimen in patients with FRα-expressing platinum-resistant ovarian cancer. Promising activity was observed for patients regardless of level of FRα expression or prior bevacizumab. These data underscore the potential for mirvetuximab soravtansine as the combination partner of choice for bevacizumab in this setting.

31 July 2013 in Cancer Research
Verified
Journal Article
Closed access
PDF file
DJDeanna M. Janzen
Deanna M. Janzen
MRMiguel A. Rosales
Miguel A. Rosales
DPDaniel Y. Paik
Daniel Y. Paik
DLDaniel S. Lee
Daniel S. Lee
DSDaniel A. Smith
Daniel A. Smith
SMSanaz Memarzadeh
Sanaz Memarzadeh
Progesterone, an agonist for the progesterone receptor (PR), can be an efficacious and well-tolerated treatment in endometrial cancer. The clinical use of progesterone is limited because of the lack of biomarkers that predict hormone sensitivity. Despite its efficacy in cancer therapy, mechanisms and site of action for progesterone remain unknown. Using an in vivo endometrial cancer mouse model driven by clinically relevant genetic changes but dichotomous responses to hormonal therapy, we show that signaling through stromal PR is necessary and sufficient for progesterone antitumor effects. Endometrial cancers resulting from epithelial loss of PTEN (PTENKO) were hormone sensitive and had abundant expression of stromal PR. Stromal deletion of PR as a single genetic change in these tumors induced progesterone resistance indicating that paracrine signaling through the stroma is essential for the progesterone therapeutic effects. A hormone-refractory endometrial tumor with low levels of stromal PR developed when activation of KRAS was coupled with PTEN-loss (PTENKO/Kras). The innate progesterone resistance in PTENKO/Kras tumors stemmed from methylation of PR in the tumor microenvironment. Add-back of stromal PR expressed from a constitutively active promoter sensitized these tumors to progesterone therapy. Results show that signaling through stromal PR is sufficient for inducing hormone responsiveness. Our findings suggest that epigenetic derepression of stromal PR could be a potential therapeutic target for sensitizing hormone-refractory endometrial tumors to progesterone therapy. On the basis of these results, stromal expression of PR may emerge as a reliable biomarker in predicting response to hormonal therapy. Cancer Res; 73(15); 4697–710. ©2013 AACR.

12 August 2025 in Med
Verified
Journal Article
Open access
YLYan-Ruide Li
Yan-Ruide Li
ZLZhe Li
Zhe Li
YZYichen Zhu
Yichen Zhu
MLMiao Li
Miao Li
YCYuning Chen
Yuning Chen
LYLili Yang
Lili Yang
Ovarian cancer (OC) poses a significant challenge for conventional chimeric antigen receptor-engineered T (CAR-T) cell therapy, due to frequent recurrence linked to tumor heterogeneity, platinum resistance, immune evasion, and an immunosuppressive tumor microenvironment (TME). Here, we analyze primary OC patient samples and identify a unique opportunity for allogeneic CAR-NKT (AlloCAR-NKT) cells to concurrently attack OC tumor cells and their TME. Leveraging stem cell gene engineering and a clinically guided culture method, we achieve robust generation of AlloCAR-NKT cells at high yield and purity. Compared to conventional CAR-T cells, AlloCAR-NKT cells demonstrate superior anti-OC efficacy, showcasing multiple OC-targeting mechanisms, focused tumor homing, and pronounced TME modulation. AlloCAR-NKT cells also exhibit a high safety profile with reduced cytokine release syndrome. Additionally, these cells do not induce graft-versus-host disease and resist host immune-cell-mediated allorejection. These findings underscore the unique efficacy and safety advantages, as well as the off-the-shelf potential of AlloCAR-NKT cell therapy for OC. Major funding was provided by the California Institute for Regenerative Medicine (CIRM).

3 August 2015 in Nature Communications
Verified
Journal Article
Open access
PDF file
DJD. M. Janzen
D. M. Janzen
ETE. Tiourin
E. Tiourin
JSJ. A. Salehi
J. A. Salehi
DPD. Y. Paik
D. Y. Paik
JLJ. Lu
J. Lu
SMSanaz Memarzadeh
Sanaz Memarzadeh
High-grade serous ovarian cancers (HGSCs) are deadly malignancies that relapse despite carboplatin chemotherapy. Here we show that 16 independent primary HGSC samples contain a CA125-negative population enriched for carboplatin-resistant cancer initiating cells. Transcriptome analysis reveals upregulation of homologous recombination DNA repair and anti-apoptotic signals in this population. While treatment with carboplatin enriches for CA125-negative cells, co-treatment with carboplatin and birinapant eliminates these cells in HGSCs expressing high levels of the inhibitor of apoptosis protein cIAP in the CA125-negative population. Birinapant sensitizes CA125-negative cells to carboplatin by mediating degradation of cIAP causing cleavage of caspase 8 and restoration of apoptosis. This co-therapy significantly improves disease-free survival in vivo compared with either therapy alone in tumour-bearing mice. These findings suggest that therapeutic strategies that target CA125-negative cells may be useful in the treatment of HGSC.